NCT02029274View on ClinicalTrials.gov

Safety and Efficacy of BAF312 in Dermatomyositis

PHASE2TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

August 25, 2013

Primary Completion Date

February 17, 2016

Study Completion Date

February 17, 2016

Conditions
Active Dermatomyositis
Interventions
DRUG

BAF312

BAF312 was provided as film-coated tablets in strengths of 0.25, 0,5, 1 and 2 mg for oral administration.

DRUG

Placebo

Matching placebo to BAF312 as tablets for oral administration.

Trial Locations (9)

33136

Novartis Investigative Site, Miami

66160

Novartis Investigative Site, Kansas City

85028

Novartis Investigative Site, Phoenix

90095

Novartis Investigative Site, Los Angeles

92868

Novartis Investigative Site, Orange

02115

Novartis Investigative Site, Boston

128 50

Novartis Investigative Site, Prague

260-8712

Novartis Investigative Site, Chiba

980-8574

Novartis Investigative Site, Sendai

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY